Metacrine
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3985 Sorrento Valley Blvd Ste C, San Die...Phone Number
(858) 369-7800Website
www.metacrine.comRevenue
$5.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company's two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH.Explore more
Metacrine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Metacrine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Metacrine has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Metacrine had a recent Job posting/layoffs
Metacrine, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Metacrine recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Metacrine launches new products
Check out if Metacrine is spiking on competitors!
Funding: Get notified immidiatlly once Metacrine has new funding data
Congratulate Masked Content for being promoted to Masked Content at Metacrine
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Metacrine
Compare insights from companies similar to Metacrine, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Metacrine is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Metacrine is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Metacrine.
Metacrine financials insights
Gather financial insights about Metacrine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$37.8M
Series A
$36M
2017
Series B
$22M
2018
Series C
$65M
2020
Stock Offering
$85M
Metacrine Tech Stack
A closer look at the technologies used by Metacrine
Most Recent Scoops
Left Company
Executive Move
Left Company
Executive Move
Mergers & Acquisitions (M&A)
Mergers & Acquisitions (M&A)
Left Company
Executive Move
Metacrine News & Media
SHAREHOLDER ALERT: Weiss Law Reminds MTCR, OFIX, APEN, and TCFC Shareholders About Its Ongoing Investigations
NEW YORK, Dec. 30, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor New...Metacrine, Equillium Agree To Terminate Merger Deal - RTTNews
Metacrine, Inc. (MTCR) and Equillium, Inc. (EQ) announced the mutual termination of definitive merger agreement. Metacrine shares rise 5.40% to $0.4551 in the after-hours trading following scrapped Equillium deal.SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor New...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Metacrine
Sign Up For FreeTo access detailed company insights
Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Com... Read More
